The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a ...
Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for the bleeding condition.
CDMO Live takes place at Rotterdam’s World Trade Center on May 7-8, 2025. It will bring together Europe’s top pharmaceutical outsourcing decision-makers, shining a spotlight on this rapidly growing ...
"Any place that gets cut, it's going to have an impact, because there's not any spare personnel at FDA,” said former agency ...
Originally scheduled for next week, the meeting of agency advisers will be delayed to give more time for public comment, an HHS spokesperson said.
Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more ...
The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through ...
Chris Gibson, Recursion’s head, cited the role small business grants played in helping his company grow its business.
A Missouri district court judge said stopping the FTC’s suit against Caremark, Express Scripts and Optum Rx would be “against ...
Scott Whitaker sent a letter to HHS calling for staff cuts at the FDA to be reversed, arguing patient care and U.S.
Layoffs at the FDA’s device center could add “months, if not years” to the time it takes to bring products to market, one attorney said.